FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 2, 2014, Pages 104-116

  Huang, Chen ^a,b   Du, Jiawei ^c   Xie, Keping ^b  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c JIANGSU UNIVERSITY   (China)

Author keywords

FOXM1; Metastasis; Pancreatic cancer; Progression; Transcription factor

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DOCETAXEL; FORKHEAD BOX M1; FORKHEAD BOX M1A; FORKHEAD BOX M1B; FORKHEAD BOX M1C; FORKHEAD TRANSCRIPTION FACTOR; GENISTEIN; KRUPPEL LIKE FACTOR 4; MICRORNA; PEPTIDE INHIBITOR; PROTEASOME INHIBITOR; THIAZOLE ANTIBIOTIC; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AUTOREGULATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HYPOXIA; METASTASIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOGENE; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

FOXM1; METASTASIS; PANCREATIC CANCER; PROGRESSION; TRANSCRIPTION FACTOR;

DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84893026665     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.01.002     Document Type: Review

References (142)

1. Stathis A., Moore M.J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol. 2010, 7:163-172.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
3. Yeo T.P., Hruban R.H., Leach S.D., Wilentz R.E., Sohn T.A., Kern S.E., Iacobuzio-Donahue C.A., Maitra A., Goggins M., Canto M.I., Abrams R.A., Laheru D., Jaffee E.M., Hidalgo M., Laheru D., Jaffee E.M., Hidalgo M., Yeo C.J., Iacobuzio-Donahue C.A., Maitra A., Goggins M., Canto M.I., Abrams R.A., Laheru D., Jaffee E.M., Hidalgo M., Yeo C.J. Pancreatic cancer. Curr. Probl. Cancer 2002, 26:176-275.
4. Neoptolemos J.P., Cunningham D., Friess H., Bassi C., Stocken D.D., Tait D.M., Dunn J.A., Dervenis C., Lacaine F., Hickey H., Raraty M.G., Ghaneh P., Büchler M.W. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann. Oncol. 2003, 14:675-692.
5. Yokoyama Y., Nimura Y., Nagino M. Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies. Surg. Today 2009, 39:466-475.
6. Laoukili J., Stahl M., Medema R.H. FOXM1: at the crossroads of ageing and cancer. Biochim. Biophys. Acta 2007, 1775:92-102.
7. Kalin T.V., Ustiyan V., Kalinichenko V.V. Multiple faces of FOXM1 transcription factor: lessons from transgenic mouse models. Cell Cycle 2011, 10:396-405.
8. Liu M., Dai B., Kang S.H., Ban K., Huang F.J., Lang F.F., Aldape K.D., Xie T.X., Pelloski C.E., Xie K., Sawaya R., Huang S. FOXM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006, 66:3593-3602.
9. Kim I.M., Ackerson T., Ramakrishna S., Tretiakova M., Wang I.C., Kalin T.V., Major M.L., Gusarova G.A., Yoder H.M., Costa R.H., Kalinichenko V.V. The Forkhead Boxm1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 2006, 66:2153-2161.
10. Madureira P.A., Varshochi R., Constantinidou D., Francis R.E., Coombes R.C., Yao K.M., Lam E.W. The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J. Biol. Chem. 2006, 281:25167-25176.
11. Hui M.K., Chan K.W., Luk J.M., Lee N.P., Chung Y., Cheung L.C., Srivastava G., Tsao S.W., Tang J.C., Law S. Cytoplasmic Forkhead box M1 (FOXM1) in esophageal squamous cell carcinoma significantly correlates with pathological disease stage. World J. Surg. 2012, 36:90-97.
12. Zeng J., Wang L., Li Q., Li W., Bjorkholm M., Jia J., Xu D. FOXM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1. J. Pathol. 2009, 218:419-427.
13. Uddin S., Ahmed M., Hussain A., Abubaker J., Al-Sanea N., AbdulJabbar A., Ashari L.H., Alhomoud S., Al-Dayel F., Jehan Z., Bavi P., Siraj A.K., Al-Kuraya K.S. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am. J. Pathol. 2011, 178:537-547.
14. Guan P., Chen H., Li H.J., Duan J., Chen J.Y. Expression and significance of FOXM1 in human cervical cancer: a tissue micro-array study. Clin. Invest. Med. 2011, 34:E1-E7.
15. Lok G.T., Chan D.W., Liu V.W., Hui W.W., Leung T.H., Yao K.M., Ngan H.Y. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One 2011, 6:e23790.
16. Xia J.T., Wang H., Liang L.J., Peng B.G., Wu Z.F., Chen L.Z., Xue L., Li Z., Li W. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas 2012, 41:629-635.
17. Koo C.Y., Muir K.W., Lam E.W. FOXM1: from cancer initiation to progression and treatment. Biochim. Biophys. Acta 2012, 1819:28-37.
18. Wang Z., Ahmad A., Li Y., Banerjee S., Kong D., Sarkar F.H. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat. Rev. 2010, 36:151-156.
19. Hruban R.H., Goggins M., Parsons J., Kern S.E. Progression model for pancreatic cancer. Clin. Cancer Res. 2000, 6:2969-2972.
20. Brugge W.R., Lauwers G.Y., Sahani D., Fernandez-del Castillo C., Warshaw A.L. Cystic neoplasms of the pancreas. N. Engl. J. Med. 2004, 351:1218-1226.
21. Maitra A., Fukushima N., Takaori K., Hruban R.H. Precursors to invasive pancreatic cancer. Adv. Anat. Pathol. 2005, 12:81-91.
22. Xie K., Wei D., Huang S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev. 2006, 17:147-156.
23. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
24. Nebert D.W. Transcription factors and cancer: an overview. Toxicology 2002, 181-182:131-141.
25. Jr J.E. Darnell, Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2:740-749.
26. Redell M.S., Tweardy D.J. Targeting transcription factors for cancer therapy. Curr. Pharm. Des. 2005, 11:2873-2887.
27. Shi Q., Le X., Abbruzzese J.L., Peng Z., Qian C.N., Tang H., Xiong Q., Wang B., Li X.C., Xie K. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 2001, 61:4143-4154.
28. Jia Z., Gao Y., Wang L., Li Q., Zhang J., Le X., Wei D., Yao J.C., Chang D.Z., Huang S., Xie K. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res. 2010, 70:1111-1119.
29. Huang C., Xie K. Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev. 2012, 23:25-35.
30. Wei D., Kanai M., Huang S., Xie K. Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis 2006, 27:23-31.
31. Wei D., Wang L., Kanai M., Jia Z., Le X., Li Q., Wang H., Xie K. KLF4alpha up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer. Gastroenterology 2010, 139:2135-2145.
32. Huang C., Cao J., Huang K.J., Zhang F., Jiang T., Zhu L., Qiu Z.J. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cell in vitro. Cancer Sci. 2006, 97:1417-1423.
33. Huang C., Jiang T., Zhu L., Liu J., Cao J., Huang K.J., Qiu Z.J. STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo. Int. J. Oncol. 2011, 38:1637-1644.
34. Huang C., Yang G., Jiang T., Cao J., Huang K.J., Qiu Z.J. Down-regulation of STAT3 expression by vector-based small interfering RNA inhibits pancreatic cancer growth. World J. Gastroenterol. 2011, 17:2992-3001.
35. Huang C., Huang R., Chang W., Jiang T., Huang K., Cao J., Sun X., Qiu Z. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma 2012, 59:52-61.
36. Bhat U.G., Jagadeeswaran R., Halasi M., Gartel A.L. Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells. J. Biol. Chem. 2011, 286:41425-41433.
37. Clark K.L., Halay E.D., Lai E., Burley S.K. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 1993, 364:412-420.
38. Korver W., Roose J., Clevers H. The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Res. 1997, 25:1715-1719.
39. Ye H., Kelly T.F., Samadani U., Lim L., Rubio S., Overdier D.G., Roebuck K.A., Costa R.H. Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues. Mol. Cell. Biol. 1997, 17:1626-1641.
40. Yao K.M., Sha M., Lu Z., Wong G.G. Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. J. Biol. Chem. 1997, 272:19827-19836.
41. Zhang Y., Zhang N., Dai B., Liu M., Sawaya R., Xie K., Huang S. FOXM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res. 2008, 68:8733-8742.
42. Dai B., Pieper R.O., Li D., Wei P., Liu M., Woo S.Y., Aldape K.D., Sawaya R., Xie K., Huang S. FOXM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res. 2010, 70:2951-2961.
43. Raychaudhuri P., Park H.J. FOXM1: a master regulator of tumor metastasis. Cancer Res. 2011, 71:4329-4933.
44. Park H.J., Carr J.R., Wang Z., Nogueira V., Hay N., Tyner A.L., Lau L.F., Costa R.H., Raychaudhuri P. FOXM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 2009, 28:2908-2918.
45. Major M.L., Lepe R., Costa R.H. Forkhead Box M1B (FOXM1B) transcriptional activity requires binding of CDK/cyclin complexes for phosphorylation-dependent recruitment of p300/CBP co-activators. Mol. Cell. Biol. 2004, 24:2649-2661.
46. Chen Y.J., Dominguez-Brauer C., Wang Z., Asara J.M., Costa R.H., Tyner A.L., Lau L.F., Raychaudhuri P. A conserved phosphorylation site within the forkhead domain of FOXM1B is required for its activation by cyclin-CDK1. J. Biol. Chem. 2009, 284:30695-30707.
47. Fu Z., Malureanu L., Huang J., Wang W., Li H., van Deursen J.M., Tindall D.J., Chen J. Plk1-dependent phosphorylation of FOXM1 regulates a transcriptional programme required for mitotic progression. Nat. Cell Biol. 2008, 10:1076-1082.
48. Ma R.Y., Tong T.H., Cheung A.M., Tsang A.C., Leung W.Y., Yao K.M. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J. Cell Sci. 2005, 118:795-806.
49. Zhang N., Wei P., Gong A., Chiu W.T., Lee H.T., Colman H., Huang H., Xue J., Liu M., Wang Y., Sawaya R., Xie K., Yung W.K., Medema R.H., He X., Huang S. FOXM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011, 20:427-442.
50. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
51. Pellegata N.S., Sessa F., Renault B., Bonato M., Leone B.E., Solcia E., Ranzani G.N. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994, 54:1556-1560.
52. Casey G., Yamanaka Y., Friess H., Kobrin M.S., Lopez M.E., Buchler M., Beger H.G., Korc M. P53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett. 1993, 69:151-160.
53. Sachdeva M., Zhu S., Wu F., Wu H., Walia V., Kumar S., Elble R., Watabe K., Mo Y.Y. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3207-3212.
54. Pandit B., Halasi M., Gartel A.L. P53 negatively regulates expression of FOXM1. Cell Cycle 2009, 8:3425-3427.
55. Barsotti A.M., Prives C. Pro-proliferative FOXM1 is a target of p53-mediated repression. Oncogene 2009, 28:4295-4305.
56. Kalinichenko V.V., Major M.L., Wang X., Petrovic V., Kuechle J., Yoder H.M., Dennewitz M.B., Shin B., Datta A., Raychaudhuri P., Costa R.H. FOXM1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004, 18:830-850.
57. Salgado H., Santos-Zavaleta A., Gama-Castro S., Millan-Zarate D., Diaz-Peredo E., et al. RegulonDB (version 3.2): transcriptional regulation and operon organization in Escherichia coli k-12. Nucleic Acids Res. 2001, 29:72-74.
58. Becskei A., Serrano L. Engineering stability in gene networks by autoregulation. Nature 2000, 405:590-593.
59. Hermsen R., Ursem B., ten WPR Combinatorial gene regulation using auto-regulation. PLoS. Comput. Biol. 2010, 6:e1000813.
60. Halasi M., Gartel A.L. A novel mode of FOXM1 regulation: positive auto-regulatory loop. Cell Cycle 2009, 8:1966-1967.
61. Li Q., Jia Z., Wang L., Kong X., Li Q., Guo K., Tan D., Le X., Wei D., Huang S., Mishra L., Xie K. Disruption of Klf4 in villin-positive gastric progenitor cells promotes formation and progression of tumors of the antrum in mice. Gastroenterology 2012, 142:531-542.
62. Kong X., Li L., Li Z., Le X., Huang C., Jia Z., Cui J., Huang S., Wang L., Xie K. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Cancer Res. 2013, 73:3987-3996.
63. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
64. Zhang X., Zeng J., Zhou M., Li B., Zhang Y., Huang T., Wang L., Jia J., Chen C. The tumor suppressive role of miRNA-370 by targeting FOXM1 in acute myeloid leukemia. Mol. Cancer 2012, 11:56.
65. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5835.
66. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
67. Xia L.M., Huang W.J., Wang B., Liu M., Zhang Q., Yan W., Zhu Q., Luo M., Zhou Z.Z., Tian D.A. Transcriptional up-regulation of FOXM1 in response to hypoxia is mediated by HIF-1. J. Cell. Biochem. 2009, 106:247-256.
68. Akakura N., Kobayashi M., Horiuchi I., Suzuki A., Wang J., Chen J., Niizeki H., Kawamura Ki., Hosokawa M., Asaka M. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001, 61:6548-6554.
69. Kretschmer C., Sterner-Kock A., Siedentopf F., Schoenegg W., Schlag P.M., Kemmner W. Identification of early molecular markers for breast cancer. Mol. Cancer 2011, 10:15.
70. Wonsey D.R., Follettie M.T. Loss of the forkhead transcription factor FOXM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 2005, 65:5181-5189.
71. Kalin T.V., Wang I.C., Ackerson T.J., Major M.L., Detrisac C.J., Kalinichenko V.V., Lyubimov A., Costa R.H. Increased levels of the FOXM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 2006, 66:1712-1720.
72. Yoshida Y., Wang I.C., Yoder H.M., Davidson N.O., Costa R.H. The forkhead boxM1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 2007, 132:1420-1431.
73. Wang I.C., Meliton L., Tretiakova M., Costa R.H., Kalinichenko V.V., Kalin T.V. Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene 2008, 27:4137-4149.
74. Gusarova G.A., Wang I.C., Major M.L., Kalinichenko V.V., Ackerson T., Petrovic V., Costa R.H. A cell-penetrating ARF peptide inhibitor of FOXM1 in mouse hepatocellular carcinoma treatment. J. Clin. Invest. 2007, 117:99-111.
75. Galderisi U., Jori F.P., Giordano A. Cell cycle regulation and neural differentiation. Oncogene 2003, 22:5208-5219.
76. Ye H., Holterman A.X., Yoo K.W., Franks R.R., Costa R.H. Premature expression of the winged helix transcription factor HFH-11B in regenerating mouse liver accelerates hepatocyte entry into S phase. Mol. Cell. Biol. 1999, 19:8570-8580.
77. Wang X., Hung N.J., Costa R.H. Earlier expression of the transcription factor HFH-11B diminishes induction of p21(CIP1/WAF1) levels and accelerates mouse hepatocyte entry into S-phase following carbon tetrachloride liver injury. Hepatology 2001, 33:1404-1414.
78. Wang Z., Banerjee S., Kong D., Li Y., Sarkar F.H. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007, 67:8293-8300.
79. Wang Z., Ahmad A., Banerjee S., Azmi A., Kong D., Li Y., Sarkar F.H. FOXM1 is a novel target of a natural agent in pancreatic cancer. Pharm. Res. 2010, 27:1159-1168.
80. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
81. Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994, 8:9-22.
82. Sah N.K., Khan Z., Khan G.J., Bisen P.S. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006, 244:164-171.
83. Wang I.C., Chen Y.J., Hughes D., Petrovic V., Major M.L., Park H.J., Tan Y., Ackerson T., Costa R.H. Forkhead box M1 regulates the transcriptional network of genes essential formitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 2005, 25:10875-10894.
84. Radhakrishnan S.K., Bhat U.G., Hughes D.E., Wang I.C., Costa R.H., Gartel A.L. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006, 66:9731-9735.
85. Huang C., Xie D., Cui J., Li Q., Yong G. FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System. Clin. Cancer Res. 2014, (in press).
86. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
87. Volpert O.V., Dameron K.M., Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997, 14:1495-1502.
88. Li Q., Zhang N., Jia Z., Le X., Dai B., Wei D., Huang S., Tan D., Xie K. Critical role and regulation of transcription factor FOXM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009, 69:3501-3509.
89. Grunstein J., Roberts W.G., Mathieu-Costello O., Hanahan D., Johnson R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 1999, 59:1592-1598.
90. Karadedou C.T., Gomes A.R., Chen J., Petkovic M., Ho K.K., Zwolinska A.K., Feltes A., Wong S.Y., Chan K.Y., Cheung Y.N., Tsang J.W., Brosens J.J., Khoo U.S., Lam E.W. FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene 2012, 31:1845-1858.
91. Prager G.W., Breuss J.M., Steurer S., Olcaydu D., Mihaly J., Brunner P.M., Stockinger H., Binder B.R. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ. Res. 2004, 94:1562-1570.
92. Margheri F., Chilla A., Laurenzana A., Serrati S., Mazzanti B., Saccardi R., Santosuosso M., Danza G., Sturli N., Rosati F., Magnelli L., Papucci L., Calorini L., Bianchini F., Del R.M., Fibbi G. Endothelial progenitor cell-dependent angiogenesis requires localization of the full-length form of uPAR in caveolae. Blood 2011, 118:3743-3755.
93. de Bock C.E., Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 2004, 24:13-39.
94. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med. Res. Rev. 2001, 21:146-170.
95. Gorantla B., Asuthkar S., Rao J.S., Patel J., Gondi C.S. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol. Cancer Res. 2011, 9:377-389.
96. Wu Q.F., Liu C., Tai M.H., Liu D., Lei L., Wang R.T., Tian M., Lu Y. Knockdown of FOXM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol. Sin. 2010, 31:361-366.
97. Ahmad A., Wang Z., Kong D., Ali S., Li Y., Banerjee S., Ali R., Sarkar F.H. FOXM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res. Treat. 2010, 122:337-346.
98. Larue L., Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005, 24:7443-7454.
99. Hugo H., Ackland M.L., Blick T., Lawrence M.G., Clements J.A., Williams E.D., Thompson E.W. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 2007, 213:374-383.
100. Bao B., Wang Z., Ali S., Kong D., Banerjee S., Ahmad A., Li Y., Azmi A.S., Miele L., Sarkar F.H. Over-expression of FOXM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J. Cell. Biochem. 2011, 112:2296-2306.
101. Huang C., Qiu Z., Wang L., Peng Z., Jia Z., Logsdon C.D., Le X., Wei D., Huang S., Xie K. A novel FOXM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res. 2012, 72:655-665.
102. Hermann P.C., Bhaskar S., Cioffi M., Heeschen C. Cancer stem cells in solid tumors. Semin. Cancer Biol. 2010, 20:77-84.
103. Ischenko I., Seeliger H., Kleespies A., Angele M.K., Eichhorn M.E., Jauch K.W., Bruns C.J. Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbeck's Arch. Surg. 2010, 395:1-10.
104. Lee C.J., Dosch J., Simeone D.M. Pancreatic cancer stem cells. J. Clin. Oncol. 2008, 26:2806-2812.
105. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
106. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
107. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
108. Garzon R., Fabbri M., Cimmino A., Calin G.A., Croce C.M. MicroRNA expression and function in cancer. Trends Mol. Med. 2006, 12:580-587.
109. Cano A., Nieto M.A. Non-coding RNAs take centre stage in epithelial to mesenchymal transition. Trends Cell Biol. 2008, 18:357-359.
110. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
111. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 2006, (12):895-904.
112. Chandran U.R., Ma C., Dhir R., Bisceglia M., Lyons-Weiler M., Liang W., Michalopoulos G., Becich M., Monzon F.A. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007, 7:64.
113. Chu X.Y., Zhu Z.M., Chen L.B., Wang J.H., Su Q.S., Yang J.R., Lin Y., Xue L.J., Liu X.B., Mo X.B. FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem. 2012, (114):755-762.
114. Yang D.K., Son C.H., Lee S.K., Choi P.J., Lee K.E., Roh M.S. Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance. Hum. Pathol. 2009, 40:464-470.
115. Bellelli R., Castellone M.D., Garcia-Rostan G., Ugolini C., Nucera C., Sadow P.M., Nappi T.C., Salerno P., Cantisani M., Basolo F., Gago T.A., Salvatore G., Santoro M. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr. Relat. Cancer 2012, 19:695-710.
116. Dai B., Kang S.H., Gong W., Liu M., Aldape K.D., Sawaya R., Huang S. Aberrant FOXM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 2007, 26:6212-6219.
117. Xia L., Huang W., Tian D., Zhu H., Zhang Y., Hu H., Fan D., Nie Y., Wu K. Upregulated FOXM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J. Hepatol. 2012, 57:600-612.
118. Pilarsky C., Wenzig M., Specht T., Saeger H.D., Grutzmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004, 6:744-750.
119. Gartel A.L. The oncogenic transcription factor FOXM1 and anticancer therapy. Cell Cycle 2012, 11:1-2.
120. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
121. Leung R.K., Whittaker P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 2005, 107:222-239.
122. Uprichard S.L. The therapeutic potential of RNA interference. FEBS Lett. 2005, 579:5996-6007.
123. Millour J., Constantinidou D., Stavropoulou A.V., Wilson M.S., Myatt S.S., Kwok J.M., Sivanandan K., Coombes R.C., Medema R.H., Hartman J., Lykkesfeldt A.E., Lam E.W. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 2010, 29:2983-2995.
124. Halasi M., Gartel A.L. Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS One 2012, 7:e31761.
125. Bhat U.G., Halasi M., Gartel A.L. Thiazole antibiotics target FOXM1 and induce apoptosis in human cancer cells. PLoS One 2009, 4:e5592.
126. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5:297-309.
127. Nencioni A., Grunebach F., Patrone F., Ballestrero A., Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007, 21:30-36.
128. Gartel A.L. A new target for proteasome inhibitors: FOXM1. Expert Opin. Investig. Drugs 2010, 19:235-242.
129. Bhat U.G., Halasi M., Gartel A.L. FOXM1 is a general target for proteasome inhibitors. PLoS One 2009, 4:e6593.
130. Wente M.N., Eibl G., Reber H.A., Friess H., Buchler M.W., Hines O.J. The proteasome inhibitor MG132 induces apoptosis in human pancreatic cancer cells. Oncol. Rep. 2005, 14:1635-1638.
131. Matsuo Y., Sawai H., Ochi N., Yasuda A., Sakamoto M., Takahashi H., et al. Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig. Dis. Sci. 2010, 55:1167-1176.
132. Tang Z.Y., Wu Y.L., Gao S.L., Shen H.W. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J. Surg. Res. 2008, 145:111-123.
133. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Jr Dunner K., Huang P., Abbruzzese J.L., McConkey D.J. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 2005, 65:11658-11666.
134. Lee J.K., Ryu J.K., Yang K.Y., Woo S.M., Park J.K., Yoon W.J., Lee S.H., Jeong K.S., Kim Y.T., Yoon Y.B. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer. Pancreas 2011, 40:966-973.
135. Yeung B.H., Huang D.C., Sinicrope F.A. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J. Biol. Chem. 2006, 281:11923-11932.
136. Sarkar F.H., Li Y. The role of isoflavones in cancer chemoprevention. Front. Biosci. 2004, 9:2714-2724.
137. Lyseng-Williamson K.A., Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 2005, 65:2513-2531.
138. Clarke S.J., Rivory L.P. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 1999, 36:99-114.
139. Michael A., Syrigos K., Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis. 2009, 12:13-16.
140. Li Y., Hussain M., Sarkar S.H., Eliason J., Li R., Sarkar F.H. Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells. BMC Cancer 2005, 5:7.
141. Li Y., Hong X., Hussain M., Sarkar S.H., Li R., Sarkar F.H. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol. Cancer Ther. 2005, 4:389-398.
142. Li Y., Zhang S., Huang S. FOXM1: a potential drug target for glioma. Future Oncol. 2012, 8:223-226.